Description
This assay uses the Luminex® 200™ platform.
Explore the most comprehensive cytokine and chemokine profile available with the Human Cytokine/Chemokine 96-Plex Discovery Assay® Array (HD96)! This advanced array features two assays conducted simultaneously from a single small sample volume: HD48A and HD48B. By running both assays concurrently, we deliver efficient, high-quality results, providing insights from two distinct assays with a rapid turnaround time.
The HD96 assay offers an unparalleled, broad, and detailed view of the circulating immune microenvironment across a wide range of both acute and chronic inflammatory conditions, as well as autoimmune and autoinflammatory diseases. It excels in research on complex diseases such as cancer, autoimmune disorders, cardiovascular diseases, and chronic infections.
For example, biomarkers like IL-6 and TNFα are crucial for studying chronic inflammatory diseases such as rheumatoid arthritis and lupus, while VEGF-A and PDGF-AA are key to exploring tumor angiogenesis and progression. Additionally, the panel facilitates the characterization of type 1 (Th1), type 2 (Th2), and type 3 (Th17) immunity, enhancing your understanding of the immune response.
If you’re unsure of which biomarkers to focus on, the HD96 panel’s broad scope allows you to detect a wide range of targets and identify key biomarkers, which can then be refined in follow-up assays for more targeted analysis. This versatile and affordable option provides a broad array of insights, optimizing your workflow and accelerating your research outcomes.
Discover the power of precision with our assay, expertly designed for the Luminex® 200™ platform. This cutting-edge technology enables the simultaneous detection of multiple biomarkers from a minimal single sample, delivering comprehensive insights with unmatched efficiency. Streamline your research and unlock a new level of detail with our advanced multiplex assay solution.
Recommended Dilution: Most samples are run undiluted, however RANTES has high concentrations in serum and plasma. If this target is important to your study and your sample type is serum or plasma, it is recommended to run samples in a separate assay with a dilution factor applied or utilize our Human Supplemental Biomarker 10-Plex (HDHSB10).
If you expect your samples to have low cytokine levels, i.e. normal healthy populations, you may wish to inquire about a High Sensitivity panel.
Click here for information on shipping biological samples for Discovery Assays
Published Research Featuring Our HD96:
- Smith, L., Gonzalez Santiago, E., Eke, C., Gu, W., Wang, W., Llivichuzhca-Loja, D., Kehoe, T., St Denis, K., Strine, M., Taylor, S., Tseng, G., & Konnikova, L. (2024). Human milk supports robust intestinal organoid growth, differentiation, and homeostatic cytokine production. Gastro Hep Advances. Advance online publication.
- Chui, M. K., Schneider, K., Miclau, K., LaHue, S. C., Furman, D., Leutwyler, H., & Newman, J. C. (2024). Associations of systemic inflammation and senescent cell biomarkers with clinical outcomes in older adults with schizophrenia. medRxiv.
- Krumholz, H. M., Sawano, M., Bhattacharjee, B., Caraballo, C., Khera, R., Li, S.-X., Herrin, J., Coppi, A., Holub, J., Henriquez, Y., Johnson, M. A., Goddard, T. B., Rocco, E., Hummel, A. C., Mouslmani, M. A. L., Putrino, D. F., Carr, K. D., Carvajal-Gonzalez, S., Charnas, L., De Jesus, M., & Iwasaki, A. (2024). The PAX LC trial: A decentralized, phase 2, randomized, double-blind study of nirmatrelvir/ritonavir compared with placebo/ritonavir for long COVID. The American Journal of Medicine.
NOTE: Results will not directly correlate with the previous HD42 or HD65 assay, as a result of the antibody systems being optimized in this new panel. If you are in need of the previous HD42 or HD65 assay in order to correlate with past data, please contact us directly.